​

IRulya Therapeutics (IRLA) Stock Forecast, Price Target & Predictions

OverviewChart

IRLA Stock Forecast

IRulya Therapeutics (IRLA) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $70.00, with a high of $72.00 and a low of $68.00. This represents a 73.83% increase from the last price of $40.27.

IRLA Stock Rating

IRulya Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (40.00%), 4 Hold (40.00%), 2 Sell (20.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 2 4 4 Strong Sell Sell Hold Buy Strong Buy

IRLA Price Target Upside V Benchmarks

TypeNameUpside
StockIRulya Therapeutics73.83%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts133
Avg Price Target$72.00$70.00$70.00
Last Closing Price$40.27$40.27$40.27
Upside/Downside78.79%73.83%73.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26261--9
Sep, 26162--9
Aug, 26-52--7
Jul, 26-43--7
Jun, 26-33--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 09, 2026Raymond James$72.00$29.36145.23%78.79%
Aug 20, 2026Craig-Hallum$68.00$34.5796.70%68.86%
Aug 18, 2026Olivia Brayer SaundersCantor Fitzgerald$70.00$32.91112.70%73.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 09, 2026Raymond JamesOutperforminitialise
Sep 29, 2026CitigroupMarket OutperformMarket Outperformhold
Sep 24, 2026Rodman & RenshawBuyBuyinitialise
Sep 22, 2026CitigroupPerformOutperformupgrade
Aug 20, 2026Craig-HallumBuyinitialise
Aug 18, 2026Cantor FitzgeraldOverweightOverweighthold
Jul 29, 2026OppenheimerOutperformOutperforminitialise
Jun 25, 2026Cantor FitzgeraldOverweightOverweighthold
Jun 23, 2026Cantor FitzgeraldOverweightinitialise
Jan 30, 2026CitigroupMarket PerformPerformdowngrade

Financial Forecast

EPS Forecast

$-350 $-280 $-210 $-140 $-70 $0 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29 Dec 30
Dec 25Dec 26Dec 27Dec 28Dec 29Dec 30
Reported$-336.00-----
Avg Forecast$-218.84$-9.20$-4.57$-4.73$-4.71$-5.32
High Forecast$-218.84$-6.99$-4.41$-2.36$-4.71$-5.32
Low Forecast$-218.84$-10.78$-4.77$-10.36$-4.71$-5.32
Surprise %53.54%-----

Revenue Forecast

Dec 25 Dec 26 Dec 27 Dec 28 Dec 29 Dec 30
Dec 25Dec 26Dec 27Dec 28Dec 29Dec 30
Reported------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

Net Income Forecast

$-85M $-68M $-51M $-34M $-17M $0 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29 Dec 30
Dec 25Dec 26Dec 27Dec 28Dec 29Dec 30
Reported$-83.98M-----
Avg Forecast$-54.82M$-2.22M$-1.15M$-1.59M$-1.18M$-1.33M
High Forecast$-54.82M$-1.75M$-1.10M$-591.98K$-1.18M$-1.33M
Low Forecast$-54.82M$-2.70M$-1.20M$-2.59M$-1.18M$-1.33M
Surprise %53.20%-----

IRLA Forecast FAQ

Is IRulya Therapeutics stock a buy?

IRulya Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 4 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that IRulya Therapeutics is a favorable investment for most analysts.

What is IRulya Therapeutics's price target?

IRulya Therapeutics's price target, set by 10 Wall Street analysts, averages $70 over the next 12 months. The price target range spans from $68 at the low end to $72 at the high end, suggesting a potential 73.83% change from the previous closing price of $40.27.

How does IRulya Therapeutics stock forecast compare to its benchmarks?

IRulya Therapeutics's stock forecast shows a 73.83% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for IRulya Therapeutics over the past three months?

  • October 2026: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 11.11% Strong Buy, 66.67% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 71.43% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.

What is IRulya Therapeutics’s EPS forecast?

IRulya Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-9.2, marking a -97.26% decrease from the reported $-336 in 2025. Estimates for the following years are $-4.57 in 2027, $-4.73 in 2028, $-4.71 in 2029, and $-5.32 in 2030.

What is IRulya Therapeutics’s revenue forecast?

IRulya Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, followed by $0 for 2028, $0 for 2029, and $0 for 2030.

What is IRulya Therapeutics’s net income forecast?

IRulya Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-2.225M, representing a -97.35% decrease from the reported $-83.979M in 2025. Projections indicate $-1.149M in 2027, $-1.593M in 2028, $-1.18M in 2029, and $-1.331M in 2030.